NasdaqGS:EXELBiotechs
Exelixis (EXEL): Has the Recent Share Price Surge Closed the Valuation Gap?
Exelixis (EXEL) has quietly turned into one of those stocks that reward patient holders, with shares up around 33% over the past year and gains accelerating over the past 3 years.
See our latest analysis for Exelixis.
That strength is not a one week wonder, with a 7 day share price return of 8.37% and a one year total shareholder return of 33.07% backing up a powerful three year total shareholder return of 179.85%. This suggests momentum is still building rather than fading at a latest share...